What is the latest price of Trastuzumab in Germany in 2024?

Fam-trastuzumab deruxtecan-nxki (Fam-trastuzumab deruxtecan-nxki) is an antibody drug conjugate (ADC) targeting the HER2 target and is used to treat patients with HER2-positive breast cancer, non-small cell lung cancer, and gastric cancer. Deruxtecan-nxki is an innovative drug that consists of two parts: one part is trastuzumab, which is a monoclonal antibody against the HER2 target. By binding to the HER2 protein, it can block its signaling pathway, thereby inhibiting the growth of tumor cells; the other part is the cytotoxic drug deruxtecan-nxki, which can target tumor cells expressing HER2. By combining these two parts, trastuzumab is able to work even better.

Detrastuzumab, as a representative of the new generation of anti-cancer drugs, has been launched in China, but it is still classified as a strictly managed drug and has not yet been included in the medical insurance system. The price of each box of 100mg is about 10,000 yuan or more. Turning to the Hong Kong market, the pricing of Trastuzumab shows a certain degree of transparency. It is reported that the Hong Kong version and the Hong Kong original version of trastuzumab are priced at about 15,000 yuan per box of 100 mg. The ingredients of these drugs are basically the same. Of course, these prices will also be affected by exchange rate fluctuations, resulting in certain fluctuations.

Trastuzumab provides a new treatment option for patients with HER2-positive cancer. Although trastuzumab has a clear price in the Hong Kong market, no generic version has yet been produced and marketed. This means that patients may need to bear high financial pressure when seeking treatment with this drug.